Enzychem Lifesciences Corporation
KOE: 183490.KQ0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Ki-Young Sohn
- Employees
- 122
- Headquarters
- Seoul, South Korea
- IPO year
- 2017
- Market cap
- ₩76.2B
- Website
- http://www.enzychem.com
Loading 183490…
Loading profile data…Frequently asked questions about 183490
What does Enzychem Lifesciences Corporation (183490.KQ) do?
Enzychem Lifesciences Corporation, a pharmaceutical company, focuses on the development of oral small molecule therapies for patients with unmet medical needs for oncology, metabolic diseases, and inflammatory diseases in South Korea. It is also developing potential therapies based on EC-18 technology platform to treat chemotherapy-induced neutr...
Where does 183490.KQ trade?
Enzychem Lifesciences Corporation (183490.KQ) trades on the KOSDAQ.
What sector is 183490.KQ in?
Enzychem Lifesciences Corporation (183490.KQ) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Enzychem Lifesciences Corporation?
Ki-Young Sohn is the chief executive officer of Enzychem Lifesciences Corporation (183490.KQ).
Where is Enzychem Lifesciences Corporation headquartered?
Enzychem Lifesciences Corporation is headquartered in South Korea.
Does 183490.KQ pay a dividend?
Enzychem Lifesciences Corporation (183490.KQ) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 183490.KQ go public?
Enzychem Lifesciences Corporation (183490.KQ) completed its initial public offering in 2017.